Evidence map›Paper›PMID 40277362›Full record

ArticleMicrobiology spectrum2025

Activity of contezolid against methicillin-resistant

Sebastian C Herren, Melissa J Karau, Christina Koscianski, Kerryl E Greenwood-Quaintance, Jayawant N Mandrekar, Wen Wang, Robin Patel

Abstract readLetter
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sebastian C Herren *Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0009-0002-2570-4250
Melissa J Karau *Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6021-4033
Christina KoscianskiDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Kerryl E Greenwood-QuaintanceDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Jayawant N MandrekarDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
Wen WangDepartment of Biology, MicuRx Pharmaceuticals Inc., Shanghai, China.
Robin PatelDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6344-4141

Funding

MicuRx PharmaceuticalsSwiss National Science Foundation P500PM_214215
6 · The paper itself

Abstract

Contezolid has activity against methicillin-resistant

Indexed as

Anti-Bacterial AgentsForeign BodiesMethicillin-Resistant Staphylococcus aureusOsteomyelitisStaphylococcal InfectionsAnimalsDisease Models, AnimalMaleRatsRifampinVancomycinAnti-Bacterial AgentsRifampinVancomycincontezolidMethicillin-resistant Staphylococcus aureus (MRSA)osteomyelitisratrifampinvancomycin

Identifiers

PMID40277362
PMCPMC12131758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.